- Benjamin R. Cowen, PhD, MBA
Chief Executive Officer
Dr. Cowen has 20 years experience working with private, early-stage biotechnology companies and public companies including, Shire and Merck, where he held a of number management positions and received recognition for leading high-performance teams and successfully completing key business development transactions. Dr. Cowen most recently served as the Vice President of Corporate Development at Milestone Pharmaceuticals, where he played a key role in a Series B financing and was responsible for business development and commercial activities. Dr. Cowen has also served on Atrin Pharmaceuticals’ Board of Directors since its inception in 2012. Dr. Cowen received his Ph.D. from University of Illinois at Urbana Champaign, his MBA from Carnegie Mellon University, his BA at Brandeis University and was an NIH Post-Doctoral Fellow at the Univ of Pennsylvania.
- Sanghee Yoo, Ph.D.
Vice President, Head of Biology
Prior to joining ImmunoMet, Dr. Yoo served as the Head of the New Drug Development Team at HanAll Biopharma, leading and managing drug development projects targeting cancer metabolism and fibrosis. She has more than 20 years of working experiences in cystic fibrosis, pain, and oncology and has shown successful leadership in projects ranging from target selection to clinical candidate nomination in several biotech companies including ProQR (Netherlands), Vertex Pharmaceuticals, Aurora Biosciences and Arcaris. Sanghee obtained her Ph.D. in biochemistry from the University of Utah, Salt Lake City, for work on protein-protein interactions between human cyclophilin A and HIV-1 capsid.
- Dr. Filip Janku, MD, PhD.
Clinical Consultant (Part time)
Dr. Janku is an Assistant Professor in the Department of Investigational Cancer Therapeutics at MD Anderson Cancer Center where he has been leading clinical trials for six years. He has been the principal investigator for numerous phase I protocols, most of which involve new developmental therapeutics with an emphasis on novel biologic and targeted molecules for the treatment of patients with various types of cancer. Dr. Janku has published over 148 articles in highly-respected, peer-reviewed journals. Dr. Janku's academic research interests focus on poof-of-concept clinical trials that possess a pivotal correlative component especially those involving oncogenic mutations by next generation sequencing, PI3K/AKT/mTOR pathway and Autophagy targets and OXPHOS inhibition pathway. He received MD/PhD from Charles University, Prague, Czech Republic and did a Clinical Research Fellowship at Investigational Cancer Therapeutics, the University of Texas, MD Anderson Cancer Center.
- Anthony A. Hörning
Business Advisor (Part time)
In 2014, Anthony A. Hörning founded Strategic Transactions Advisory AG (Basel, Switzerland) and since 2015, has been a Senior Advisor at Vantage Partners LLP (Boston, USA).
As Head of Alliance Management, he was in charge of the preparation, launch and ongoing implementation, as well as of all renegotiations, of Novartis Pharma global alliances and created a widely recognized alliance skills training program. He served for many years as a member of the board of the “Association of Strategic Alliance Professionals“. Prior to his career in Business Development & Licensing, Mr. Hörning was CFO of Novartis in Brazil and Head of Investor Relations & Capital Markets for the former Sandoz AG in Switzerland. He gained his initial training in international capital markets as a Vice-President with JPMorgan. He holds a Masters Degree in Business Administration from the University of Zürich.
Copyright © ImmunoMet. All rights reserved.